- Home
- FORA vs ABVC Comparison
FORA vs ABVC Comparison
Compare FORA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ABVC
- Stock Information
- Founded
- FORA 2014
- ABVC 2015
- Country
- FORA United States
- ABVC United States
- Employees
- FORA N/A
- ABVC N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- ABVC Health Care
- Exchange
- FORA Nasdaq
- ABVC Nasdaq
- Market Cap
- FORA 59.9M
- ABVC 52.1M
- IPO Year
- FORA N/A
- ABVC N/A
- Fundamental
- Price
- FORA $1.92
- ABVC $2.75
- Analyst Decision
- FORA Strong Buy
- ABVC
- Analyst Count
- FORA 1
- ABVC 0
- Target Price
- FORA $5.00
- ABVC N/A
- AVG Volume (30 Days)
- FORA 13.3K
- ABVC 581.7K
- Earning Date
- FORA 08-13-2025
- ABVC 08-13-2025
- Dividend Yield
- FORA N/A
- ABVC N/A
- EPS Growth
- FORA N/A
- ABVC N/A
- EPS
- FORA N/A
- ABVC N/A
- Revenue
- FORA $22,332,001.00
- ABVC $508,383.00
- Revenue This Year
- FORA $46.25
- ABVC $735.18
- Revenue Next Year
- FORA $11.30
- ABVC N/A
- P/E Ratio
- FORA N/A
- ABVC N/A
- Revenue Growth
- FORA 5.22
- ABVC 1904.43
- 52 Week Low
- FORA $1.85
- ABVC $0.40
- 52 Week High
- FORA $4.03
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- FORA 43.99
- ABVC 47.16
- Support Level
- FORA $1.92
- ABVC $2.90
- Resistance Level
- FORA $2.06
- ABVC $3.18
- Average True Range (ATR)
- FORA 0.07
- ABVC 0.32
- MACD
- FORA -0.00
- ABVC -0.16
- Stochastic Oscillator
- FORA 4.76
- ABVC 23.53
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.